11/24/2025
The FDA has granted 510(k) clearance for TMS as an adjunctive treatment for Major Depressive Disorder in young people ages 15–21.
Real-world data from more than 1,100 patients across 35 centers showed strong safety and meaningful improvement in depression symptoms.
This clearance expands access to a much-needed, noninvasive treatment option for younger patients and supports continued innovation in neuromodulation.
👉 Read the full Healio article here:
https://www.healio.com/news/psychiatry/20251119/fda-grants-510k-clearance-for-tms-as-adjunctive-for-major-depressive-disorder-in-young-people